Differences in Clinical Manifestations, Antimicrobial Susceptibility Patterns, and Mutations of Fluoroquinolone Target Genes between Chryseobacterium gleum and Chryseobacterium indologenes.

infections are uncommon, and previous studies have revealed that is frequently misidentified as We aimed to explore the differences in clinical manifestations and antimicrobial susceptibility patterns between and The database of a clinical microbiology laboratory was searched to identify patients with infections between 2005 and 2017. Species were reidentified using 16S rRNA gene sequencing, and patients with and infections were included in the study. A total of 42 and 84 isolates were collected from consecutive patients. A significant increase in incidence was observed. was significantly more associated with bacteremia than Patients with infections had more comorbidities of malignancy and liver cirrhosis than those with infections. The overall case fatality rate was 19.8%. Independent risk factors for mortality were female sex and infection. These isolates were most susceptible to minocycline (73%), followed by trimethoprim-sulfamethoxazole (47.6%), tigecycline (34.1%), and levofloxacin (32.5%). exhibited a significantly higher rate of susceptibility than to piperacillin, piperacillin-tazobactam, ceftazidime, tigecycline, and levofloxacin. Alterations in DNA gyrase subunit A were identified to be associated with fluoroquinolone resistance in No nonsynonymous substitutions were observed in the quinolone resistance-determining regions (QRDRs) of Differences in epidemiology, clinical manifestations, and antimicrobial susceptibility patterns exist between and Additional investigations are needed to explore the significance of these differences.